

Latest developments on products and services from the industry. To have your news included contact Patricia McDonnell at Oncology News on T/F: +44 (0)288 289 7023, E: patricia@oncologynews.biz

Varian Honored Among World's 100 Most Sustainable Corporations for Second Year Running

Varian Medical Systems have been honoured for its commitment to sustainability with inclusion on a prestigious list of the world's most sustainable companies for the second year in a row. Varian remains the highest ranked US healthcare equipment company among the Corporate Knights Global 100 Most Sustainable Corporations list, announced during the World Economic Forum at Davos, Switzerland.

"We are proud to be recognised once again for our commitment to sustainability and this will spur us on to continually improve our efforts," says Dow Wilson (pictured), Varian's



chief executive officer. "Our company's mission is to help save lives around the world and we seek to do this in ways that benefit the communities in which we operate."

"The inclusion of Varian in the Global 100 ranking for the second time in a row is a reflection of its continuous dedication to sustainability," said Michael Yow, director of research at Corporate Knights. "Once again, Varian is an industry leader in terms of sustainability performance and disclosure."

The 2015 Varian Sustainability Report can be found here: <https://www.varian.com/about-varian/citizenship>

Provectus Biopharmaceuticals confirms first patients dosed in trials of PV-10 for melanoma

Provectus Biopharmaceuticals, Inc confirmed in January 2016 that patients have been dosed in both its Phase 3 clinical trial of PV-10, Provectus' novel investigational drug for cancer, for Stage III locally advanced cutaneous melanoma and its Phase 1b/2 clinical trial of PV-10 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with Stage IV melanoma. In addition, the Company confirmed that it continues to enroll patients in all of its active oncology studies.

Eric Wachter, Chief Technology Officer of Provectus, said, "With patients starting treatment in both of these studies, the clock is ticking to interim results and ultimately the completion of these studies. Our recruitment activities are moving ahead and we are hopeful

that these studies will play critical roles in demonstrating effectiveness and safety of PV-10 in melanoma."

PHASE 3 STUDY

The Phase 3 study is an international multicenter, open-label, randomised controlled trial (RCT) of single-agent intralesional (IL) PV-10 versus systemic chemotherapy to assess treatment of locally advanced cutaneous melanoma in patients who are BRAF V600 wild-type and have failed or are not otherwise candidates for ipilimumab or another immune checkpoint inhibitor. Subjects in the PV-10 arm receive IL PV-10 to all of their melanoma lesions. Subjects in the comparator arm receive the investigator's choice of dacarbazine or temozolomide as determined by investigator preference and/or local availability of the agent.

For more details on the study, please visit <https://www.clinicaltrials.gov/ct2/show/NCT02288897>.

PROVECTUS
BIOPHARMACEUTICALS, INC.

Provectus Biopharmaceuticals announces immunology data on PV-10 in colon cancer, presented at 11th Annual ASC Meeting

Provectus Biopharmaceuticals, Inc have announced that an abstract discussing the immunologic effects of PV-10 on colon cancer cells was presented at the 11th Annual Academic Surgical Congress in February 2-4, 2016, at the Hyatt Regency in Jacksonville, Florida.

The abstract, titled "PV-10 Induces Potent Immunogenic Apoptosis in Colon Cancer Cells," was presented by Dr AV Maker. It is co-authored by NM Kunda, J Qin and G Qiao, working out of the University of Illinois at Chicago, Division of Surgical Oncology, Department of Surgery, College of Medicine, Chicago, IL, USA. The team of authors also includes B Prabhakar of the University of Illinois at Chicago, Department of Microbiology & Immunology, College of Medicine, Chicago, IL, USA. Dr Maker belongs to both departments.

The abstract can be found at: <http://www.asc-abstracts.org/abs2016/2-01-pv-10-induces-potent-immunogenic-apoptosis-in-colon-cancer-cells/>

To have your event or news featured in the magazine contact Patricia McDonnell – E: patricia@oncologynews.biz

Oncology
news
 Find us on
Facebook
<http://is.gd/oncologyfacebook>

PROVECTUS
BIOPHARMACEUTICALS, INC.

A New Chapter for Genesis Care in the UK

Following its acquisition by Australia's largest provider of radiotherapy services, Cancer Partners UK has become Genesis Care. It has also launched its ninth centre in the UK, West Malling Diagnostic & Treatment Centre, in Kent.

With a focus on delivering early diagnosis, unparalleled patient care and rapid access to treatments, including chemotherapy and world-class radiotherapy, the new centre follows a similar model to the company's latter two in Milton Keynes and Oxford.

Paul McPartlan, who has recently been appointed UK General Manager, says: "I am looking forward to the benefits Genesis Care will deliver for cancer patients, with a focus on innovation, the sharing of global best practice and investment in the latest technology and treatment techniques. In addition, we are really looking forward to collaborative working with our NHS partners, so that we can provide the best possible results for patients across the UK, closer to their home and workplace.

"I'm also excited at the opportunities it



will bring to our staff. Sharing best practice across all job roles, greater learning, and a real focus on research and development means they will be able to play a significant part in the company's growth."

For further information please contact:

Beth Rankine T: +44 (0)7809 603 751

E: beth.rankine@genesiscare.co.uk

W: www.genesiscare.co.uk



Brain Tumour Research have moved

National charity Brain Tumour Research has relocated to headquarters in central Milton Keynes. Since inception in 2009 the charity has enjoyed a period of remarkable growth and its previous base in rural Buckinghamshire became no longer fit for purpose for a charity striving to make a real difference for those diagnosed with the biggest cancer killer of children and adults under 40.

The charity's eye catching branding and strong key messages have been incorporated into an office space that motivates staff and volunteers alike and provides visitors with an inspirational vision of the charity's ambitions.

A launch event in January was attended by the Mayor of Milton Keynes, Iain Stewart MP for Milton Keynes South and representatives of the city's business community who were all able to hear from principal scientists at the dedicated brain tumour research centres that the charity funds. They were also able to see how the new office space enables staff and volunteers to fulfil the orders pouring in for



badges, wristbands and other merchandise as we approach the UK's premier brain tumour awareness event Wear A Hat Day which this year is Thursday March 24th.

For further information visit:

<http://www.braintumourresearch.org/> or

E: info@braintumourresearch.org

Old red dye shows promise as new cancer foe



Modern cancer drugs supercharge immune systems, target specific gene mutations and pack modified viruses into vaccines. Amid the increasing sophistication, one investigational treatment stands out for its simplicity.

Rose Bengal, a cheap industrial chemical that turns yarn and food bright red, has been used as a diagnostic staining agent for some time. Now, some scientists are looking at its potential to fight various forms of cancer.

At the forefront is Provectus Biopharmaceuticals Inc, which is testing a reformulated version of the industrial dye on melanoma, the deadliest form of skin cancer. The company reported promising results in a small melanoma study.

While some doctors are encouraged by the research, government approval is years off and not guaranteed. The company must replicate its early results on a bigger scale, and a US Food and Drug Administration decision is not expected before 2019.

Rose Bengal's potential against cancer was discovered by accident. The salt was first patented in 1882 as a wool dye and has been used for years as a diagnostic stain in tests for jaundice in newborns and to detect eye damage.

In 1998, scientists who later founded Provectus were looking for a safe photoreactive agent to use in an investigation of lasers against cancer. Rose Bengal fit the bill.

As it turned out, the Rose Bengal solution appeared to work on its own to dissolve tumours when directed injectively into them, recalled Provectus Chief Technology Officer Eric Wachter, a former scientist from Oak Ridge National Lab who co-founded the company. "It made the lasers obsolete."

For further information visit:

www.pvct.com

Provectus Biopharmaceuticals announces data on PV-10 and co-inhibitory blockade to be presented at AACR Annual Meeting 2016

Provectus Biopharmaceuticals, Inc announced that data on intralesional PV-10 and co-inhibitory blockade in a melanoma model will be presented at the American Association for Cancer Research's ("AACR") Annual Meeting 2016 on Wednesday, April 20, 2016, from 8 am to 12 Noon Central Standard Time.

The poster presentation is titled "T Cell Mediated Immunity after Combination Therapy

with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model." Scheduled for presentation at Section 26 of the exhibition area, the data are from a team of researchers at the H Lee Moffitt Cancer Center in Tampa, led by Dr Shari Pilon-Thomas.

The AACR Annual Meeting 2016 is being held at the Ernest N Morial Convention Center in New Orleans, Louisiana, from April 16-20, 2016.

The complete press release is available at www.pvct.com/pressrelease.html?article=20160224.1 on the Provectus website: www.pvct.com



Provectus Biopharmaceuticals initiating Phase 1 study of PV-10 in neuroendocrine tumours metastatic to liver

Provectus Biopharmaceuticals, Inc are initiating a protocol titled, "A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products."

The 12-patient phase 1 study will run up to 48 months with interim data anticipated at the half-way point of the two-cohort study. Patients in the first of the two successive cohorts will receive PV-10 to a single NET tumour in their liver, while patients in the second cohort may receive PV-10 to multiple NET tumours. Timothy Price, MD will serve as principal investigator for the study at The Queen Elizabeth Hospital in Woodville, South Australia.

Dr Price explained, "The primary endpoint of our study will be assessment of safety and tolerability of PV-10 in the treatment



of these metastatic NETs. Our secondary endpoints address preliminary efficacy, disease symptoms and biomarkers, and include assessments of Objective Response Rate (ORR) of injected and uninjected tumours; change in tumour biomarkers (somatostatin receptor expression, chromogranin A and 5-hydroxyindole acetic acid); change in NET symptoms assessed by standard quality of life instruments; and possible change in peripheral blood mononuclear cells (PBMCs)."

For further information, please visit <https://www.clinicaltrials.gov/ct2/show/NCT02693067>. The study is expected to open for enrollment in March 2016.

Provectus Biopharmaceuticals awarded patent extending protection of the PV-10 manufacturing process

Provectus Biopharmaceuticals, Inc announced several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H Craig Dees, PhD.

Provectus believes that this patent, wholly owned by Provectus and conferring coverage to at least 2031, will provide further protection around the proposed commercial process for manufacturing PV-10. Investigational drug product generated using this proprietary technology is being used in all ongoing clinical trials of PV-10, including the pivotal phase 3 trial in melanoma (NCT02288897).

Provectus' efforts to bring this process development to fruition were supported by Cambrex Charles City, Inc, a subsidiary of Cambrex Corporation, a life sciences company that provides products and services that accelerate and improve the development and commercialisation of new and generic therapeutics.

Dr Kurt Kiewel, Director of R&D at Cambrex Charles City, said, "We feel fortunate to bring the depth of our experience in custom development and API manufacturing to support promising investigational products like PV-10. It has been our pleasure to work with the innovative scientists at Provectus to help advance this potential new cancer treatment toward the market."

The complete press release is available at www.pvct.com/pressrelease.html?article=20160301.1



Beating Bowel Cancer announces details of London Patient Day

Beating Bowel Cancer's 11th annual London Patient Day will take place on Saturday 16 April at The Royal College of Surgeons, London.

The event offers bowel cancer patients, their carers and colorectal clinical nurse specialists a day of support, education and inspiration.

The programme will include a selection of talks by eminent health professionals and interactive workshops on every aspect of living with bowel cancer. They include:

Mr Peter Dawson – Consultant Colorectal Surgeon, Chelsea & Westminster NHS Foundation Trust, presenting on: "Advances in bowel surgery"

Dr Jonathan Hoare – Consultant Gastroenterologist, St Mary's Hospital, Imperial NHS Trust, presenting on "What can be done

down the scope? What colonoscopy can contribute to the management and prevention of bowel cancer"

Dr Robert Thomas – Consultant Oncologist, Bedford & Addenbrooke's Hospitals, presenting on "Lifestyle after cancer - self-help strategies".

The exhibition hall will include all kinds of goods and services that improve quality of life for bowel cancer patients.

If you know of any patients who would benefit from attending, or you are a colorectal clinical nurse specialist who is interested, please visit: www.beatingbowelcancer.org/patient-day-london-2016 for further details and to register for the day.



ScheBo® • Tumor M2-PK™ Stool Test & ScheBo® • M2-PK Quick™

Bringing sensitivity to bowel cancer screening

"In conclusion, faecal M2-PK, either as an ELISA or as a lateral rapid flow test, is a cost-effective and easy-to-perform routine test." Tonus, C. et al. World J Gastroenterology, 2012.

Can detect non-bleeding, as well as bleeding, polyps and tumours.

Further information from: Ivor Smith, ScheBo® • Biotech UK Ltd, PO Box 6359, Basingstoke, RG22 4WE
Tel: 01256 477259 Fax: 01256 327889 E-mail: i.smith@schebo.co.uk www.schebo.co.uk